Skip to main content
MarketStoryBook

BDX in “GLP-1 Eats Everything”

Becton, Dickinson and Company

Bull sideFadingExposure: not rated yet

Higher use of injectable obesity medicines expands the addressable market for pen needles and other drug-delivery components.

BDX impact map — “GLP-1 Eats Everything”

How this story travels from the headline to BDX’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.

Loading BDX impact map…

Price history, marked with story events

Oct 20, 2025 – Oct 19, 2026 · 245 sessions

Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions

Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…

Full story

GLP-1 Eats Everything

Appetite suppression as a macro variable.

BULL side — Higher use of injectable obesity medicines expands the addressable market for pen needles and other drug-delivery components.

Read the full GLP-1 Eats Everything story

Bull side

2 stories
  • BDX in “GLP-1 Eats Everything”

    FadingExposure: not rated yet
    Viewing

    Appetite suppression as a macro variable.

    Higher use of injectable obesity medicines expands the addressable market for pen needles and other drug-delivery components.

  • Managed Care's Margin Machine Breaks

    BDX in “Managed Care's Margin Machine Breaks”

    FadingExposure: not rated yet

    Rising utilization, tougher reimbursement and scrutiny of denials are shifting economics from insurers back to care providers.

    Rising hospital admissions and treatment intensity increase consumption of its needles, catheters, medication-management products and laboratory supplies.

Bear side

0 stories

No bear-side stories for BDX yet.